Harpoon Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HARP research report →
Companywww.harpoontx.com
Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors.
- CEO
- Julie M. Eastland
- IPO
- 2019
- Employees
- 45
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $865.08M
- P/E
- -1.14
- P/S
- 27.11
- P/B
- 14.14
- EV/EBITDA
- -12.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.30%
- Op Margin
- -214.08%
- Net Margin
- -210.36%
- ROE
- -211.56%
- ROIC
- -285.53%
Growth & Income
- Revenue
- $31.91M · 34.92%
- Net Income
- $-67,137,000 · 59.66%
- EPS
- $-20.24 · 60.75%
- Op Income
- $-68,325,000
- FCF YoY
- 26.77%
Performance & Tape
- 52W High
- $23.21
- 52W Low
- $3.11
- 50D MA
- $20.73
- 200D MA
- $10.76
- Beta
- 1.55
- Avg Volume
- 1.13M
Get TickerSpark's AI analysis on HARP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 11, 24 | New Leaf Biopharma Opportunities II, L.P. | sell | 299,430 |
| Mar 11, 24 | New Leaf Biopharma Opportunities II, L.P. | sell | 395,783 |
| Mar 11, 24 | New Leaf Biopharma Opportunities II, L.P. | sell | 10,000 |
| Mar 11, 24 | New Leaf Biopharma Opportunities II, L.P. | sell | 85,750 |
| Mar 11, 24 | SILVERNAIL LAUREN P | sell | 5,000 |
| Mar 11, 24 | SILVERNAIL LAUREN P | sell | 2,033 |
| Mar 11, 24 | SILVERNAIL LAUREN P | sell | 2,300 |
| Mar 8, 24 | HUNT RONALD | other | 424 |
| Mar 11, 24 | HUNT RONALD | sell | 10,000 |
| Mar 11, 24 | HUNT RONALD | sell | 299,430 |
Our HARP Coverage
We haven't published any research on HARP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HARP Report →